Deep Dive: CGRP Therapies: First-Line Status, New Safety Signal

The landscape for migraine treatment changed significantly as of March 2024. The American Headache Society updated its position statement to designate CGRP-targeted therapies as a first-line option for migraine prevention. This change removes the requirement for patients to try and fail older, non-specific preventives like topiramate or beta-blockers before accessing these newer treatments. A patient presenting with four migraine days a month now has a clinical basis to start on a CGRP agent immediately.

This shift in prescribing standards brings new clinical responsibilities. With eight FDA-approved agents now available, including four monoclonal antibodies and four gepants, clinicians must navigate different routes of administration, dosing schedules, and interaction profiles. The current roster includes injectable options like erenumab, fremanezumab, galcanezumab, and eptinezumab, alongside oral and intranasal gepants such as ubrogepant, rimegepant, atogepant, and zavegepant.

As these therapies move to the front line, vigilance regarding emerging safety signals is necessary. A 2025 analysis of the FDA Adverse Event Reporting System identified a signal for Raynaud phenomenon across the class, with certain agents showing higher reporting odds ratios. While initial concerns regarding hypertension prompted label updates, systematic reviews of real-world data indicate that significant risks for normotensive patients appear low, though clinicians should monitor those with pre-existing hypertension.

Since the data for these safety signals came from patient populations who had already failed multiple previous treatments, the expansion into a first-line setting requires closer observation. These medications represent a move away from the cycle of poor tolerability associated with older preventives, but they are not a universal fix. Clinicians are encouraged to evaluate each patient's specific needs against the pharmacokinetics and delivery methods of the eight available agents to determine the appropriate treatment path.